DelveInsight’s “Neurotrophic Keratitis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Neurotrophic Keratitis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Neurotrophic Keratitis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Neurotrophic Keratitis: An Overview
Neurotrophic keratitis (NK), which is also known as neurotrophic Keratitis or trigeminal neuropathic keratopathy, is a rare degenerative corneal disease, characterized by symptoms like lack of or decreased corneal sensation, corneal epithelial breakdown, and impaired healing that results into increased susceptibility of the corneal surface to injury and compromised healing. In severe cases, this can also lead to stromal melting, corneal ulceration, and even perforation.
Neurotrophic keratitis can be classified into three stages according to the Mackie classification. This staging is based on the severity of corneal damage, increasing from stage 1 to stage 3. This staging of neurotrophic keratitis is characterized by epithelial changes (stage 1), persistent epithelial defects (stage 2), and a corneal ulcer (stage 3).
Neurotrophic Keratitis Market Key Facts
According to a large-population, retrospective cohort study by Gabison et al. (2018), to evaluate the prevalence, etiologies, outcomes, and clinical management of neurotrophic keratitis in a tertiary referral eye hospital within the target population, the incidence of Neurotrophic Keratitis was 5.79/10,000.
According to the research study by Stanisic et al. (2018), Neurotrophic keratitis is an orphan disease with an estimated prevalence across the EU of less than 5 in 10,000 individuals. Due to its rarity, there is also a general paucity of evidence on Neurotrophic Keratitis. The estimated incidence and prevalence are below 1.6/10,000.
The total diagnosed prevalence of Neurotrophic Keratitis in the 7MM was ~101,500 in 2021.
The total prevalent and diagnosed prevalent population of Neurotrophic Keratitis in the 7MM was recorded highest in the US in 2021.
Among the 7MM, in 2021, the lowest prevalent population of Neurotrophic Keratitis was recorded in Spain.
In 2021, Japan had a total of ~12,500 cases prevalent for Neurotrophic Keratitis, out of which ~8,300 cases were actually diagnosed for Neurotrophic Keratitis.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Neurotrophic Keratitis market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Neurotrophic Keratitis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Neurotrophic Keratitis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Neurotrophic Keratitis Epidemiology, Segmented as –
Total Prevalent Cases of Neurotrophic Keratitis in the 7MM [2019–2032]
Gender-specific Diagnosed Prevalent Cases of Neurotrophic Keratitis in the 7MM [2019–2032]
Stage-specific Diagnosed Prevalent Cases of Neurotrophic Keratitis in the 7MM [2019–2032]
Total Diagnosed Prevalent Cases of Neurotrophic Keratitis in the 7MM [2019–2032]
Neurotrophic Keratitis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Neurotrophic Keratitis market or expected to be launched during the study period. The analysis covers the Neurotrophic Keratitis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Neurotrophic Keratitis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Latest Key Update in the Neurotrophic Keratitis Therapeutics Market
On April 12, 2023, RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx” or “Company”) announced that the first patient of Phase 3 clinical trial (SEER-2) of RGN-259, a novel treatment for neurotrophic keratitis (NK), has been enrolled and begun treatment. The product candidate is under development by ReGenTree, LLC, a U.S. joint venture between RegeneRx and HLB Therapeutics.
Learn How the Neurotrophic Keratitis Market Will Evolve and Grow by 2032 @
The Leading Players in the Neurotrophic Keratitis Therapeutics Market Include:
Oyster Point Pharma
Recordati Rare Diseases
And Many Others
Neurotrophic Keratitis Therapies Covered in the Report Include:
OXERVATE (Cenegermin-bkbj/rhNGF): Dompé Farmaceutici
OC-01(varenicline/Chantix): Oyster Point Pharma
REC 0559 (MT-8/Udonitrectag/ REC 0/0559): Recordati Rare Diseases/MimeTech
CSB-001: Claris Biotherapeutics
RGN-259 (Tβ4): ReGenTree
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Neurotrophic Keratitis Competitive Intelligence Analysis
4. Neurotrophic Keratitis Market Overview at a Glance
5. Neurotrophic Keratitis Disease Background and Overview
6. Neurotrophic Keratitis Patient Journey
7. Neurotrophic Keratitis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Neurotrophic Keratitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Neurotrophic Keratitis Unmet Needs
10. Key Endpoints of Neurotrophic Keratitis Treatment
11. Neurotrophic Keratitis Marketed Products
12. Neurotrophic Keratitis Emerging Drugs and Latest Therapeutic Advances
13. Neurotrophic Keratitis Seven Major Market Analysis
14. Attribute Analysis
15. Neurotrophic Keratitis Market Outlook (In US, EU5, and Japan)
16. Neurotrophic Keratitis Access and Reimbursement Overview
17. KOL Views on the Neurotrophic Keratitis Market
18. Neurotrophic Keratitis Market Drivers
19. Neurotrophic Keratitis Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic healthcare market today @ Healthcare Partner Identification Solutions
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States